Search Results

You are looking at 11 - 20 of 265 items for :

  • "expectancy" x
  • Refine by Access: All x
Clear All
Full access

In Chemotherapy for Lung Cancer, Sometimes Less is More

Eric Roeland, Charles Loprinzi, Timothy J. Moynihan, Thomas J. Smith, and Jennifer Temel

on life expectancy in advanced NSCLC. Although oncologists understand that chemotherapy leads to net harm in patients who are completely bedridden, when this net harm begins is not clear. A better understanding of this issue, through additional

Full access

Costs and Benefits of Extended Endocrine Strategies for Premenopausal Breast Cancer

Janice S. Kwon, Gary Pansegrau, Melica Nourmoussavi, Geoffrey L. Hammond, and Mark S. Carey

effective in terms of overall life expectancy compared with tamoxifen alone for low-risk premenopausal women with ER-positive breast cancer. 6 However, for high-risk women requiring chemotherapy, OA/AI was more costly but more effective than tamoxifen alone

Full access

Predicting All-Cause Mortality in Women With and Without Breast Cancer Using the Schonberg Index: A Women’s Health Initiative Study

Rebecca A. Nelson, Enrique Soto-Perez-de-Celis, Rowan T. Chlebowski, Mara Schonberg, Joanne Mortimer, Kathy Pan, Lifang Hou, Marian L. Neuhouser, Kerryn W. Reding, Nazmus Saquib, Jean Wactawski-Wende, Emily Wolfson, Mina S. Sedrak, and Laura Kruper

Background Many older adults with cancer have concurrent medical illnesses that can affect both their cancer treatment and their prognosis. Failure to consider the overall life expectancy and competing causes of death in clinical decision

Full access

NCCN Guidelines Insights: Palliative Care, Version 2.2017

Maria Dans, Thomas Smith, Anthony Back, Justin N. Baker, Jessica R. Bauman, Anna C. Beck, Susan Block, Toby Campbell, Amy A. Case, Shalini Dalal, Howard Edwards, Thomas R. Fitch, Jennifer Kapo, Jean S. Kutner, Elizabeth Kvale, Charles Miller, Sumathi Misra, William Mitchell, Diane G. Portman, David Spiegel, Linda Sutton, Eytan Szmuilowicz, Jennifer Temel, Roma Tickoo, Susan G. Urba, Elizabeth Weinstein, Finly Zachariah, Mary Anne Bergman, and Jillian L. Scavone

. NCCN Recommendations Preparing Patients and Families for EOL and Transition to Hospice Care For patients with an estimated life expectancy of years or years to months (see PAL-27; page 991), providers should assess prognostic awareness and

Full access

Strategies for the Management of Early-Stage Breast Cancer in Older Women

Lee S. Schwartzberg and Sarah L. Blair

age alone, but also consider the patient's goals, life expectancy, and totality of morbidities.” The mandate is to avoid both undertreatment in the curative setting and toxicity in the palliative setting. “With proper support, standard therapies are

Full access

The Role of Active Surveillance in the Management of Prostate Cancer

Simon D. Fung-Kee-Fung, Sima P. Porten, Maxwell V. Meng, and Michael Kuettel

theme: low-volume, low-grade disease on prostate biopsy and low PSA. The current version of the NCCN Guidelines 2 favors AS in patients with “very low-risk” disease and a life expectancy of less than 20 years (to view the most recent version of these

Full access

Senior Adult Oncology, Version 2.2014

Arti Hurria, Tanya Wildes, Sarah L. Blair, Ilene S. Browner, Harvey Jay Cohen, Mollie deShazo, Efrat Dotan, Barish H. Edil, Martine Extermann, Apar Kishor P. Ganti, Holly M. Holmes, Reshma Jagsi, Mohana B. Karlekar, Nancy L. Keating, Beatriz Korc-Grodzicki, June M. McKoy, Bruno C. Medeiros, Ewa Mrozek, Tracey O’Connor, Hope S. Rugo, Randall W. Rupper, Rebecca A. Silliman, Derek L. Stirewalt, William P. Tew, Louise C. Walter, Alva B. Weir III, Mary Anne Bergman, and Hema Sundar

approximately 70% of all cancers will be diagnosed in adults aged 65 years or older. 3 Older adults are more prone to develop cancer than younger adults. Furthermore, aging in the US population and increased life expectancy mean that cancer in older adults is

Full access

Prostate Cancer, Version 3.2024

Featured Updates to the NCCN Guidelines

Edward M. Schaeffer, Sandy Srinivas, Nabil Adra, Yi An, Rhonda Bitting, Brian Chapin, Heather H. Cheng, Anthony Victor D’Amico, Neil Desai, Tanya Dorff, James A. Eastham, Thomas A. Farrington, Xin Gao, Shilpa Gupta, Thomas Guzzo, Joseph E. Ippolito, R. Jeffrey Karnes, Michael R. Kuettel, Joshua M. Lang, Tamara Lotan, Rana R. McKay, Todd Morgan, Julio M. Pow-Sang, Robert Reiter, Mack Roach III, Tyler Robin, Stan Rosenfeld, Ahmad Shabsigh, Daniel Spratt, Russell Szmulewitz, Benjamin A. Teply, Jonathan Tward, Richard Valicenti, Jessica Karen Wong, Jenna Snedeker, and Deborah A. Freedman-Cass

. Although active surveillance has been the preferred option for patients with very-low-risk prostate cancer who have a life expectancy >20 years, radical therapy with RP or RT have still been options for these patients. Several panel members noted that

Full access

Hypogonadism and Infertility in Testicular Cancer Survivors

Linda A. Jacobs and David J. Vaughn

-stimulating hormone, and luteinizing hormone (LH) levels have been examined in numerous populations of cancer survivors, 17 and are particularly relevant for men treated for cancer at a young age. The longer life expectancy of many young cancer survivors, including a

Full access

Prostate Cancer

James Mohler, Robert R. Bahnson, Barry Boston, J. Erik Busby, Anthony D'Amico, James A. Eastham, Charles A. Enke, Daniel George, Eric Mark Horwitz, Robert P. Huben, Philip Kantoff, Mark Kawachi, Michael Kuettel, Paul H. Lange, Gary MacVicar, Elizabeth R. Plimack, Julio M. Pow-Sang, Mack Roach III, Eric Rohren, Bruce J. Roth, Dennis C. Shrieve, Matthew R. Smith, Sandy Srinivas, Przemyslaw Twardowski, and Patrick C. Walsh

detection and treatment of prostate cancers that do not threaten life expectancy cause unnecessary side effects that impair quality of life, increase health care expenses, and decrease the value of PSA and digital rectal examination (DRE) as early detection